Recombinant CNTN2 protein as well as preparation method and application thereof

By constructing an expression system in mammalian cells and expressing CNTN2 protein using transient transfection technology, the shortcomings of prokaryotic and insect cell expression systems are solved, and efficient, stable and cost-effective protein production is achieved, suitable for large-scale production and structural research. .

CN118956958APending Publication Date: 2024-11-15SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411030857.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, when expressing CNTN2 protein, the prokaryotic expression system lacks post-eukaryotic translation modification, and the insect cell expression system is costly and difficult to scale, resulting in poor protein function, stability and positioning, and complex operation, making it difficult to meet large-scale production. need.

Method used

Using a mammalian cell expression system, a mammalian cell secretory expression vector was constructed by obtaining the full-length gene of the extracellular segment of CNTN2, and a transient transfection technology was used to express and purify the recombinant CNTN2 protein in HEK293F cells to achieve efficient, stable and rapid expression.

Benefits of technology

The high purity, uniformity and high folding stability of the recombinant CNTN2 protein are achieved, which reduces cell culture costs, is suitable for large-scale production and structural analysis, and simplifies the operation process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956958A_ABST
    Figure CN118956958A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a recombinant CNTN2 protein and a preparation method and application thereof. According to the present invention, the efficient, stable and rapid expression of the recombinant CNTN2 protein is achieved in the mammalian cell expression system by using the mammalian cell secretion type expression vector and combining the transient transfection technology, and the requirement of the mass expression of the immune protein containing the transmembrane domain in the eukaryote can be met.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a recombinant CNTN2 protein and a preparation method and application thereof. Background Art

[0002] Contactin-2 (CNTN2) is a member of the Ig superfamily cell adhesion molecules (IgCAMs) family. It has six N-terminal immunoglobulin (Ig) repeat domains, four fibronectin III (FNIII) repeat domains, and a C-terminal glycosylated phosphatidylinositol (GPI) anchor structure for anchoring it to the neuronal cell membrane. As a neuro-specific glycoprotein, CNTN2 plays a key role in the formation of axonal connections, especially in the integrity and function of myelinated axons. In order to further understand the specific mechanism of action of CNTN2 in neuronal connections and signal transduction, it is necessary to conduct in-depth research on the expression of CNTN2.

[0003] At present, existing studies mainly use prokaryotic expression systems or insect cell expression systems to obtain partial domain proteins of CNTN2. Among them, the method based on the prokaryotic expression system is to insert the target gene encoding the partial domain of CNTN2 into a plasmid vector, and then transform it into prokaryotes such as Escherichia coli for expression of recombinant proteins. This method can produce proteins quickly and on a large scale, which is suitable for high-throughput experimental needs. However, the prokaryotic expression system lacks natural post-translational modification mechanisms, such as phosphorylation, glycosylation, acetylation, signal peptide excision, and peptide segment cutting and decomposition, which may cause the expressed protein to differ from the natural protein in terms of function, stability, localization and immunogenicity.

[0004] The method based on the insect cell expression system is to insert the target gene into a baculovirus vector, and then infect insect cells such as Sf9, Sf21 or High5 cells to express some domain proteins of CNTN2. This method can express proteins that require eukaryotic post-translational modification, but the culture conditions of insect cells are complex, the cost is high, and the requirements for large-scale culture equipment are high, so it faces the challenge of large-scale production. In addition, when expressing recombinant proteins on a large scale, the titer of baculovirus directly affects the infection efficiency and protein expression level, and it is necessary to select an appropriate infection time and cooperate with multi-step infection, which is complicated, time-consuming and costly. Therefore, a lot of research is still needed to develop an appropriate CNTN2 expression system. Summary of the invention

[0005] The present invention provides a recombinant CNTN2 protein and a preparation method and application thereof by constructing a mammalian cell expression system.

[0006] Specifically, the present invention provides the following technical solutions:

[0007] The first aspect of the present invention provides a method for preparing a recombinant CNTN2 protein, comprising: S1, obtaining the full-length gene of the extracellular segment of CNTN2; S2, connecting the full-length gene of the extracellular segment of CNTN2 to a mammalian cell secretory expression vector to construct a recombinant vector; S3, using the recombinant vector to transiently transfect mammalian cells to construct a recombinant cell; and S4, using the recombinant cell to express and obtain the recombinant CNTN2 protein.

[0008] In some embodiments, in step S1, primers are used to obtain the full-length gene of the extracellular segment of CNTN2, and the primers include an upstream primer with a sequence of SEQ ID NO: 1, and a downstream primer with a sequence of SEQ ID NO: 2.

[0009] In some embodiments, in step S2, the mammalian cell secretory expression vector includes a pSecT ag2B vector.

[0010] In some embodiments, in step S3, the mammalian cells include HEK293F cells.

[0011] In some embodiments, in step S3, the transfection reagent used in the transient transfection includes polyethyleneimine.

[0012] In some embodiments, the step S4 comprises: S41, culturing the recombinant cells in a culture medium; S42, collecting the supernatant of the culture medium; S43, purifying the supernatant using nickel-nitrotriacetic acid agarose beads and imidazole elution buffer; and S44, isolating and obtaining the recombinant CNTN2 protein.

[0013] In some embodiments, in step S43, the imidazole elution buffer comprises hydroxyethylpiperazine ethanesulfonic acid, sodium chloride, dithiothreitol and imidazole in a volume ratio of (10-35):(100-350):(0.5-3.5):(100-500).

[0014] In some embodiments, the step S44 comprises performing gel filtration chromatography using hydroxyethylpiperazine ethanesulfonic acid, sodium chloride and dithiothreitol in a volume ratio of (10-35):(100-350):(0.5-3.5) to obtain the recombinant CNTN2 protein.

[0015] The second aspect of the present invention provides a recombinant CNTN2 protein obtained by the above-mentioned method for preparing the recombinant CNTN2 protein.

[0016] The third aspect of the present invention provides an application of the method for preparing the above-mentioned recombinant CNTN2 protein in antibody preparation.

[0017] The beneficial effects of the present invention are:

[0018] The present invention utilizes a mammalian cell secretory expression vector and combines it with transient transfection technology to achieve efficient, stable and rapid expression of recombinant CNTN2 protein in a mammalian cell expression system. This method can not only meet the demand for large-scale expression of immune proteins containing transmembrane domains in eukaryotic organisms, but also requires only a small amount of serum-free culture medium during cell culture, which has cost-effectiveness advantages.

[0019] Furthermore, the product obtained by the above expression system is further purified without cell disruption. The target protein can be obtained by nickel column affinity separation after collecting the cell supernatant, which is easy to operate. In addition, the obtained recombinant CNTN2 protein has high purity and homogeneity, and exhibits a high level of folding and stability, making it close to the natural state. In addition, this method is suitable for negative staining of CNTN2 protein and detection and structural analysis data collection of cryo-electron microscopy samples. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 A Superdex6 column gel filtration chromatography analysis spectrum in one embodiment;

[0021] Figure 2 It is a Coomassie brilliant blue staining detection spectrum of the SDS-PAGE analysis chromatography column elution peak sample in one embodiment;

[0022] Figure 3 The uranyl acetate staining spectrum of the elution peak sample of the chromatography column detected by transmission electron microscopy in one embodiment. DETAILED DESCRIPTION

[0023] The technical solution of this patent will be further described in detail below in conjunction with specific implementation methods. It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of this application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by ordinary technicians in the technical field to which this application belongs. Among them, primer synthesis and sequencing were completed by Shanghai Bioengineering Co., Ltd.

[0024] Example 1: CNTN2 protein expression method

[0025] (1) Cloning of CNTN2 protein gene.

[0026] According to the amino acid sequence of the full-length gene of the extracellular segment of CNTN2 (NP_001333012.1) from position 31 to position 1012, specific primers were designed, and the full-length sequence of the extracellular segment of the CNTN2 protein gene was amplified by PCR using the designed primers using human cDNA as a template to obtain PCR products. Among them, the upstream primer sequence is TCCCAAACCACCTTCGGGCCTGTC (SEQ ID NO: 1), and the downstream primer sequence is GTTCTCCACCATCATGCTTGTGCCTC (SEQ ID NO: 2).

[0027] (2) Construction of recombinant vector containing CNTN2 protein gene.

[0028] The pSecTag2B vector was used as an empty vector, and the Bwi36I and XhoI double restriction sites were selected as the multiple cloning sites for connecting exogenous genes, and based on T4 ligase, a recombinant vector containing the CNTN2 protein gene was obtained. Specifically, the pSecTag2B vector and the PCR product obtained in step (1) were digested using the Bwi36I and XhoI double enzymes provided by NEB, and incubated at 37°C for 1 hour to obtain the digestion product. The digestion products were connected using the T4 ligase provided by NEB, and continued at 16°C for 12 hours to ensure that the PCR product can be correctly connected to the pSecTag2B vector to obtain the connection product. Then, the connection product was transformed into Escherichia coli DH5α competent cells for amplification and screening to obtain a recombinant vector containing the CNTN2 protein gene.

[0029] (3) Preparation of host cells expressing recombinant CNTN2 protein.

[0030] Polyethyleneimine (PEI) is used as a transfection reagent to transfect the CNTN2 protein gene into HEK293F cells to obtain host cells expressing recombinant CNTN2 protein. Specifically, PEI and the recombinant vector containing the CNTN2 protein gene obtained in step (2) are mixed at a mass ratio of 1:1, incubated at room temperature for 20 minutes, and then added to a HEK293F cell culture medium with a cell density OD value of 1.5-2.5 for transfection to obtain HEK293F cells that can express recombinant CNTN2 protein, that is, host cells expressing the target protein.

[0031] (4) Expression of recombinant CNTN2 protein.

[0032] The host cells expressing the recombinant CNTN2 protein obtained in step (3) are cultured in SMM serum-free medium for 5 days, and the recombinant CNTN2 protein is obtained after separation.

[0033] This embodiment uses the pSecTag2B vector as a mammalian cell secretory expression vector to construct a recombinant vector containing the CNTN2 protein gene. The vector can achieve efficient and stable transient expression in mammalian host cells, ensuring that the recombinant CNTN2 protein is expressed in large quantities in a short time. In addition, the protein expressed by the pSecTag2B vector is fused with an Igκ chain leader sequence at the N-terminus, which can guide the newly synthesized recombinant CNTN2 protein into the secretory pathway of the cell and secrete it outside the cell. At the same time, the Igκ chain leader sequence of the vector contains a c-myc epitope, which allows it to be recognized by specific antibodies and is suitable for the detection of recombinant CNTN2 protein. At the same time, the six tandem histidine residues (His-tag) in the leader sequence can bind to nickel or cobalt ions, thereby achieving affinity purification of the recombinant CNTN2 protein. In order to screen successfully transformed recombinant cells, the vector also contains Zeocin TM Resistance gene, which enables recombinant cells carrying this vector to be able to grow in the presence of Zeocin TM It should be understood that in practical applications, other mammalian cell secretory expression vectors can also be used as empty vectors to connect the full-length gene of the extracellular segment of CNTN2 to achieve the construction of a recombinant vector, which should not be a limitation to the technical solution of this application.

[0034] This embodiment uses human embryonic kidney HEK293F suspension cells as mammalian cells. The cells are derived from human primary embryos and are transformed by adenovirus type 5 DNA, in which the specific E1A adenovirus gene can transactivate several viral promoters, enabling them to efficiently express recombinant CNTN2 protein. It should be understood that in practical applications, other mammalian cells can also be used as host cells to achieve the construction of recombinant cells under the mediation of transfection reagents, which should not be a limitation to the technical solution of this application.

[0035] This embodiment uses polyethyleneimine as a transfection reagent. This reagent is a highly charged cationic polymer, and its positive charge can effectively adsorb negatively charged nucleic acid molecules to form a complex and enter the cell. As a transient transfection reagent, polyethyleneimine has low cytotoxicity and high transfection efficiency, especially in HEK293 cells, so that the recombinant vector containing the CNTN2 protein gene can be efficiently transfected. It should be understood that in practical applications, other transfection reagents can also be used to mediate the transfection of recombinant vectors to mammalian cells, which should not be a limitation to the technical solution of this application.

[0036] In this embodiment, an upstream primer with a sequence of SEQ ID NO: 1 and a downstream primer with a sequence of SEQ ID NO: 2 are designed to amplify the full-length gene of the extracellular segment of CNTN2, which avoids the possibility of secondary structure formation within and between primers, and has the advantages of strong specificity, high PCR efficiency, and moderate length. In practical applications, other primer sequences can also be designed or used to achieve PCR amplification, which should not be a limitation to the technical solution of this application.

[0037] Example 2: CNTN2 protein purification method

[0038] In Example 1, recombinant CNTN2 protein was obtained by gene cloning, recombinant vector construction, host cell preparation and target protein expression. Based on Example 1, this example purified the recombinant CNTN2 protein as follows.

[0039] The culture medium containing host cells expressing recombinant CNTN2 protein was centrifuged at 4°C and 12000rpm, and the supernatant was collected. Then, the supernatant was incubated with nickel-nitrotriacetic acid agarose beads (Ni-NTA-Agarose beads), during which the target protein containing the His tag was bound to the nickel ions and captured on the Ni-NTA-Agarose beads. Then, the protein was eluted with an imidazole elution buffer, during which imidazole competitively replaced the His tag and released the target protein from the Ni-NTA-Agarose beads. Among them, the composition of the imidazole elution buffer is 10-35mM Hepes (hydroxyethylpiperazine ethanesulfonic acid) at pH 7.5, 100-350mM NaCl (sodium chloride), 0.5-3.5mM DTT (dithiothreitol) and 100-500mM imidazole (imidazole). Afterwards, a protein concentrator ultrafiltration tube with MWCO>10kDa was used as a sample concentrator tube (GE Healthcare Vivaspin) to concentrate the eluted target protein to adjust the concentration. Finally, the concentrated target protein was loaded onto a Superose6 chromatography column and eluted using a chromatography elution buffer to remove contaminating proteins and obtain recombinant CNTN2 protein. The chromatography elution buffer was composed of 10-35mM Hepes, 100-350mM NaCl, and 0.5-3.5mM DTT at a pH of 7.5.

[0040] In this embodiment, hydroxyethylpiperazine ethanesulfonic acid, sodium chloride, dithiothreitol and imidazole in a volume ratio of (10-35): (100-350): (0.5-3.5): (100-500) are used as imidazole elution buffer to purify the supernatant and release the target protein from Ni-NTA-Agarose beads. Among them, hydroxyethylpiperazine ethanesulfonic acid as a weak alkaline buffer helps to maintain appropriate pH conditions, sodium chloride helps to maintain ionic strength, dithiothreitol can help maintain the reduced state of the protein, thereby enhancing the stability of the protein, and imidazole competitively replaces the His tag, which helps to enhance the stability and solubility of the protein. In addition, the appropriate volume ratio of the components improves the elution effect and purification efficiency of the recombinant CNTN2 protein. It should be understood that in practical applications, imidazole elution buffers of other components or proportions can also be used for elution, which should not be a limitation to the technical solution of the present application.

[0041] This embodiment uses hydroxyethylpiperazine ethanesulfonic acid, sodium chloride and dithiothreitol in a volume ratio of (10-35): (100-350): (0.5-3.5) for gel filtration chromatography. Selecting this composition and volume ratio of the chromatography elution buffer for operation can effectively reduce nonspecific adsorption, reduce the binding of non-target proteins and other contaminants, thereby improving the purity and separation efficiency of the recombinant CNTN2 protein. It should be understood that in practical applications, other mixtures can also be used for gel filtration chromatography, which should not be a limitation to the technical solution of the present application.

[0042] Test result 1: Superdex6 column gel filtration chromatography analysis

[0043] Figure 1 The Superdex6 column gel filtration chromatography analysis graph is shown, where the horizontal axis is the elution volume and the vertical axis is the absorbance at 280nm. It can be seen that the main peak at 15mL is higher and has a larger area, indicating that the concentration of the recombinant CNTN2 protein is higher. In addition, there are small peaks at 11mL and 12mL with higher concentrations, which may be different protein subtypes or impurities.

[0044] Test result 2——SDS-PAGE test

[0045] Figure 2The Coomassie Brilliant Blue staining detection map of the SDS-PAGE analysis column elution peak sample is shown. It can be seen that the theoretical size of the CNTN2 protein is 110kDa, while the molecular weight of the recombinant CNTN2 protein is about 130kDa. It is speculated that the recombinant CNTN2 protein may have undergone glycosylation modification during the expression of HEK293F cells. In addition, 100mL of HEK293F cells were transfected, and the total amount of purified recombinant CNTN2 protein was 1mg, with a purity of 95%.

[0046] Test result 3——Microspectrophotometer test

[0047] The absorbance of the samples was measured using a micro-spectrophotometer (Thermo Scientific NanoDrop), and the A260 / 280 ratio was calculated.

[0048] According to statistics, the spectrophotometric value of the recombinant CNTN2 protein is 0.652±0.076, and the protein A260 / 280 ratio between 0.5-0.7 is generally regarded as having good sample purity. Therefore, the recombinant CNTN2 protein obtained based on this method has the characteristics of high purity.

[0049] Test result 4——Transmission electron microscopy test

[0050] The recombinant CNTN2 protein was diluted to 0.01-0.001 mg / mL, and 4 μL was added to a copper mesh with a carbon film. After standing for 30-60 seconds, the excess sample was removed with filter paper, followed by staining with 3% uranyl acetate, rinsing with water once, and drying at room temperature for 5 minutes. The recombinant CNTN2 protein was then detected using a 120kV transmission electron microscope (FEI, Talos L120CG2). After cryo-EM pretreatment, 5000-8000 transmission electron microscope images were screened, and 1.2-2 million high-quality and high-definition particle images were selected for analysis, and the three-dimensional protein structure of the recombinant CNTN2 protein was reconstructed.

[0051] Figure 3 The transmission electron microscopy results of the recombinant CNTN2 protein are shown. It can be seen that the recombinant CNTN2 protein shows excellent dispersibility and uniformity, the protein molecular structure is clearly visible, and there is no obvious aggregation or denaturation phenomenon, indicating that it maintains a stable conformation. The particles of the recombinant CNTN2 protein are evenly distributed, reflecting the high purity and good folding state of the protein. In addition, no obvious impurities or degradation products were observed in the transmission electron microscopy images, which further supports that the protein has excellent purity and protein activity.

[0052] The present invention further provides the use of recombinant CNTN2 protein in antibody preparation, specifically including injecting the recombinant CNTN2 protein as an immunogen into animals such as mice and rabbits, then collecting the antibodies produced by these animals, and enhancing the specificity and affinity of the antibodies through multiple immunization and mixing techniques. Since the preparation method provided by the present invention can obtain highly purified recombinant CNTN2 protein, it can significantly reduce the possibility of nonspecific immune response in animals, which helps to improve the efficiency and success rate of immunogen injection. In addition, it can also help researchers accurately determine the optimal immunogen dose, injection regimen and immunization cycle, thereby improving the specificity and affinity of the antibody.

[0053] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.

Claims

1. A method for preparing a recombinant CNTN2 protein, characterized in that: include: S1. Obtain the full-length gene of the extracellular segment of CNTN2; S2, connecting the full-length extracellular segment gene of CNTN2 to a mammalian cell secretory expression vector to construct a recombinant vector; S3, using the recombinant vector to transiently transfect mammalian cells to construct recombinant cells; and S4. Using the recombinant cell to express and obtain the recombinant CNTN2 protein.

2. The recombinant CNTN according to claim 1 2. A method for preparing protein, characterized in that: In step S1, primers are used to obtain the full-length gene of the extracellular segment of CNTN2. The primers include an upstream primer with a sequence of SEQ ID NO: 1, and a downstream primer with a sequence of SEQ ID NO:

2.

3. The method for preparing the recombinant CNTN2 protein according to claim 1, characterized in that: In the step S2, the mammalian cell secretory expression vector includes a pSecTag2B vector.

4. The method for preparing the recombinant CNTN2 protein according to claim 1, characterized in that: In the step S3, the mammalian cells include HEK293F cells.

5. The method for preparing the recombinant CNTN2 protein according to claim 4, characterized in that: In the step S3, the transfection reagent used in the transient transfection includes polyethyleneimine.

6. The recombinant CNTN according to any one of claims 1 to 5 2. A method for preparing protein, characterized in that: The step S4 comprises: S41, culturing the recombinant cell in a culture medium; S42, collecting the supernatant of the culture medium; S43, purifying the supernatant using nickel-nitrotriacetic acid agarose beads and imidazole elution buffer; and S44. Isolate and obtain the recombinant CNTN2 protein.

7. The method for preparing the recombinant CNTN2 protein according to claim 6, characterized in that: In step S43, the imidazole elution buffer comprises hydroxyethylpiperazine ethanesulfonic acid, sodium chloride, dithiothreitol and imidazole in a volume ratio of (10-35):(100-350):(0.5-3.5):(100-500).

8. The method for preparing the recombinant CNTN2 protein according to claim 7, characterized in that: The step S44 comprises performing gel filtration chromatography using hydroxyethylpiperazine ethanesulfonic acid, sodium chloride and dithiothreitol in a volume ratio of (10-35):(100-350):(0.5-3.5) to obtain the recombinant CNTN2 protein.

9. The recombinant CNTN2 protein obtained by the method for preparing the recombinant CNTN2 protein according to any one of claims 1 to 5.

10. Use of the recombinant CNTN2 protein according to claim 9 in antibody preparation.

Citation Information

Patent Citations

  • Expression method of CSTN3 protein, recombinant expression vector and recombinant HEK293F cell

    CN117448374A

  • Nucleic acid molecules encoding human contactin

    WO1995035373A2